Board Meeting Summary

Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. No. 92–463), as amended, notice is hereby given that the Federal Accounting Standards Advisory Board will hold a meeting on Thursday, December 13, and Friday, December 14, from 9:00 to 4:30 p.m. room 7C13, the comptroller General's Briefing Room, of the General Accounting Office building, 441 G St., NW, Washington, DC.

The purpose of the meeting is to discuss:

- National Defense PP&E
- Major Acquisition Program
- Required Supplementary Stewardship Information (RSSI)
- Technical Agenda Review
- Codification
- Accounting and Auditing Policy Committee Charter

Any interested person may attend the meeting as an observer. Board discussions and reviews are open to the public.

Announcement of Meeting Dates in 2000 for the Accounting and Auditing Policy Committee

Meetings are scheduled for:

January 20, 2000
March 9, 2000
May 11, 2000
July 13, 2000
September 14, 2000
November 9, 2000

Unless otherwise noted, all AAPC meetings will be in Room 4N30 at 441 G Street, NW, from 1:30 to 4:00 p.m.

FOR FURTHER INFORMATION, CONTACT: Wendy Comes, Executive Director, 441 G St., NW, Room 3B18, Washington, DC 20548, or call (202) 512–7350.

Authority: Federal Advisory Committee Act. Pub. L. No. 92–463, Section 10(a)(2), 86 Stat. 770, 774 (1972) (current version at 5 U.S.C. app. section 10(a)(2) (1988); 41 CFR 101–6.1015 (1990).

Dated: November 15, 1999.

Wendy M. Comes,

Executive Director.

[FR Doc. 99–30187 Filed 11–18–99; 8:45 am]

BILLING CODE 1610–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee for Energy-Related Epidemiologic Research and Subcommittee for Community Affairs: Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meetings.

Name: Advisory Committee for Energy-Related Epidemiologic Research (ACERER) Subcommittee for Community Affairs (SCA).

Times and Dates: 12:30 p.m.–6:45 p.m., December 13, 1999; 8:45 a.m.–5:15 p.m., December 16, 1999.

Place: Hyatt Regency Crystal City, 2799 Jefferson Davis Highway, Arlington, Virginia 22202, telephone 703/418–1234, fax 703/418–1289.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: This subcommittee advises ACERER on matters related to community needs.

Matters To Be Discussed: Agenda items will include status of the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI) follow-up to radio iodine fallout—risk communication to the American public; a panel discussion of adding doses and adding risks; and subcommittee input to the ACERER management review of the NCI Chernobyl studies.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Paul G. Renard, Executive Secretary, SCA, ACERER, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, M/S F–35, Atlanta, Georgia 30341–3724, telephone 770/488–7040, fax 770/488–7044.

Name: Advisory Committee for Energy-Related Epidemiologic Research (ACERER).

Times and Dates: 8:30 a.m.–5 p.m., December 14, 1999; 8:30 a.m.–4:30 p.m., December 15, 1999.

Place: Hyatt Regency Crystal City, 2799 Jefferson Davis Highway, Arlington, Virginia 22202, telephone 703/418–1234, fax 703/418–1289.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: This committee is charged with providing advice and recommendations to the Secretary, HHS; the Assistant Secretary for Health, HHS; the Director, CDC; and the Administrator, Agency for Toxic Substances and Disease Registry (ATSDR), on establishment of a research agenda and the conduct of a research program pertaining to energy-related epidemiologic studies.

Matters To Be Discussed: Agenda items will include presentations from the Fred Hutchinson Cancer Research Center; the National Academy of Sciences; the Consortium for Risk Evaluation and Stakeholder Participation (CRESP); the Department of Energy on overall findings of their occupational medicine reviews; the National Institute for Occupational Safety and Health on the topic of notification and risk communication; a report on the status of the CDC report to Congress on fallout; a report from the ACERER Subcommittee for Management Review of the Chernobyl Studies; a report on the current status of CDC's research agenda and the current status of the revised Memorandum of Understanding; and relevant committee discussions.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Michael J. Sage, Executive Secretary, ACERER, and Acting Deputy Director, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, M/S F–28, Atlanta, Georgia 30341–3724, telephone 770/488–7300, fax 770/488–7310.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.

Dated: November 15, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 99–30204 Filed 11–18–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention (CDC)

The Division of Birth Defects, Child Development, and Disability and Health (DBDCH); Meeting

The Division of Birth Defects, Child Development, and Disability and Health (DBDCH) in the National Center for Environmental Health (NCEH) at the Centers for Disease Control and Prevention (CDC) announces the following conference.

Name: A conference entitled Infection in Pregnancy and Neurodevelopment.

Times and Dates: 7:30 a.m.–5 p.m., Nov. 30, 1999; 7:45 a.m.–3:45 p.m., Dec. 1, 1999.

Place: The Holiday Inn Select, Hotel and Conference Plaza, 130 Clairemont Avenue, Decatur, Georgia 30030.

Status: Open for participation by anyone with an interest in Public Health issues related to Infection in Pregnancy and Neurodevelopment, limited only by the space available. Persons wishing to participate must fax their request to (770) 488–7361 and indicate if they wish to attend.

Matters To Be Discussed: A large body of evidence suggests that infection, particularly subclinical infection, of the maternal reproductive tract during pregnancy is an important cause of premature birth. There is additional evidence suggesting that fetal infection may lead to brain damage and subsequent serious neurological impairment and disability, such as cerebral palsy. One of

the strategic goals of the Developmental Disabilities Branch (DDB) is to investigate causal factors for cerebral palsy and other serious neurodevelopmental disabilities for the purposes of prevention. The proposed workshop, organized by the DDB, National Center for Environmental Health, in collaboration with the National Center for HIV, STD and TB Prevention National Center for Infectious Diseases, and the National Center for Chronic Disease Prevention and Health Promotion, is designed to assist in the development of a prevention research agenda concerning the role of maternal/fetal infection during pregnancy, especially subclinical infection, on subsequent adverse neurodevelopmental outcomes of affected offspring. The agenda would guide extramural research activities by establishing research priorities and providing a research framework for CDC's extramural partners in the area of infection in pregnancy and neurodevelopment.

Contact Persons for More Information: Diana E. Schendel, Ph.D., telephone (770) 488–7359, or Marilyn Deal, telephone (770) 488–7695, Division of Birth Defects, Child Development, and Disability and Health (DBDCH), NCEH, CDC, 4770 Buford Highway, NE, Mailstop F–15, Atlanta, Georgia 30341. Fax (770) 488–7361.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: November 15, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 99–30203 Filed 11–18–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–1109]

Mercury Compounds in Drugs and Food; List and Analysis; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a document entitled ''Mercury Compounds in Drugs and Food.'' The document discusses drugs (including biologics) and foods that contain intentionally introduced mercury compounds. In addition, for those products that contain intentionally introduced mercury compounds, the document provides a quantitative and qualitative analysis of the mercury compounds in the products. This document has been prepared in response to the Food and Drug Administration Modernization Act of 1997 (FDAMA), section 413, entitled ''Food and Drug Administration Study of Mercury Compounds in Drugs and Food.''

DATES: Written comments may be submitted at any time.

ADDRESSES: Submit written requests for single copies of the document entitled ''Mercury Compounds in Drugs and Food'' to the Drug Information Branch (HFD–210), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your requests. Copies of the document are available on the Internet at http://www.fda.gov/cder/index.htm. Submit written comments on the document to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:

For human drug products: Gerald M. Rachanow, Center for Drug Evaluation and Research (HFD–560), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–2222.

For human biological products: Robert A. Yetter, Center for Biologics Evaluation and Research (HFM–10), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0373.

For veterinary drug products: William C. Keller, Center for Veterinary Medicine (HFV–210), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–6641.

For food and dietary supplement products: Sharon A. Ross, Center for Food Safety and Applied Nutrition (HFS–456), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–205–5343.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a document entitled ''Mercury Compounds in Drugs and Food.'' This document discusses drugs (including biologics) and foods that contain intentionally introduced mercury compounds. In addition, for those products that contain intentionally introduced mercury compounds, the document provides a quantitative and qualitative analysis of the mercury compounds in the products.

This document is part of FDA's implementation of FDAMA (Public Law 105–115), enacted on November 21, 1997. Section 413 of FDAMA required FDA to: (1) Compile a list of drugs and foods that contain intentionally introduced mercury compounds, and (2) provide a quantitative and qualitative analysis of the mercury compounds in this list. FDAMA required the agency to compile the list and provide the analysis within 2 years after the date of its enactment.

The statute did not differentiate whether the mercury compound was present in a product as an active or inactive ingredient, whether the product was for human or veterinary use, or whether the product was sold by prescription or over-the-counter. Food products include dietary supplements.

In the **Federal Register** of December 14, 1998 (63 FR 68775) and April 29, 1999 (64 FR 23083), FDA published notices requesting data and information on any intentionally introduced mercury compounds in these types of products. The agency asked manufacturers of affected products to provide: (1) The commercial name of the product that contains the mercury compound; (2) the chemical name, quantitative amount, and purpose of the mercury compound present; (3) a copy of the product's labeling; and (4) an estimate of the amount of the mercury compound used annually in manufacturing the product.

The agency received 41 responses to the two request-for-data notices. The agency also reviewed information contained in its Drug Registration and Listing System and other sources to identify additional products that contain intentionally introduced mercury compounds. The document discusses the information that the agency reviewed and provides a list and analysis of the products that were identified. The document is intended to provide information and does not set forth any requirements.

II. Comments

Interested persons may, at any time, submit to the Dockets Management Branch (address above) written comments regarding this document. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments should be identified with the docket number found in brackets in the heading of this document. A copy of the document and received comments may be seen in the Dockets Management Branch between 9